A Multicenter, Open-Label, Single-Arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Trial Profile

A Multicenter, Open-Label, Single-Arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Malignant ascites; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Nov 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 12 Jun 2009 Interim results were reported in a Regeneron Pharmaceuticals media release.
    • 12 Jun 2009 Primary endpoint 'Time to additional treatment' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top